Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 55 Results

Title
Intervention Indication Therapeutic Area Year Actions
Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults Certolizumab (CDP-870; Cimzia; certolizumab pegol) Plaque psoriasis Dermatology 2017 View  |  Download
Delgocitinib for treating moderate to severe chronic hand eczema after 1 previous therapy Delgocitinib Chronic hand eczema Dermatology 2023 View  |  Download
Dersimelagon for previously untreated erythropoietic protoporphyria and X-linked protoporphyria Dersimelagon Erythropoietic protoporphyria , X-linked protoporphyria Dermatology , Haematology 2022 View  |  Download
Deucravacitinib for treating active psoriatic arthritis Deucravacitinib (BMS-986165) Psoriatic arthritis Dermatology , Rheumatology 2023 View  |  Download
Difelikefalin for pruritus associated with chronic kidney disease Difelikefalin (Korsuva; CR845) Pruritus Cardiovascular System , Dermatology , Nephrology 2020 View  |  Download
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Atopic dermatitis Dermatology 2018 View  |  Download
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Atopic dermatitis Dermatology 2019 View  |  Download
Dupilumab for treating bullous pemphigoid Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Bullous pemphigoid Dermatology 2024 View  |  Download
Dupilumab for treating Chronic Spontaneous Urticaria in people aged 12 years and older after 1 previous treatment Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Chronic spontaneous urticaria (CSU) Dermatology 2021 View  |  Download
Dupilumab for treating Prurigo Nodularis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Prurigo nodularis (PN) Dermatology 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications